Your browser doesn't support javascript.
loading
Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Reponse Exemplified by Levofloxacin.
Busse, David; Schaeftlein, André; Solms, Alexander; Ilia, Luis; Michelet, Robin; Zeitlinger, Markus; Huisinga, Wilhelm; Kloft, Charlotte.
Afiliación
  • Busse D; Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry, Freie Universitaet Berlin, Berlin, Germany.
  • Schaeftlein A; Graduate Research Training program PharMetrX, Berlin/Potsdam, Germany.
  • Solms A; Havelland Kliniken GmbH, Hospital Pharmacy, Nauen, Germany.
  • Ilia L; Institute of Mathematics, University of Potsdam, Potsdam, Germany.
  • Michelet R; Clinical Pharmacometrics, Bayer AG, Berlin, Germany.
  • Zeitlinger M; Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry, Freie Universitaet Berlin, Berlin, Germany.
  • Huisinga W; Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry, Freie Universitaet Berlin, Berlin, Germany.
  • Kloft C; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Pharm Res ; 38(3): 381-395, 2021 Mar.
Article en En | MEDLINE | ID: mdl-33723793
PURPOSE: Systematic comparison of analysis methods of clinical microdialysis data for impact on target-site drug exposure and response. METHODS: 39 individuals received a 500 mg levofloxacin short-term infusion followed by 24-h dense sampling in plasma and microdialysate collection in interstitial space fluid (ISF). ISF concentrations were leveraged using non-compartmental (NCA) and compartmental analysis (CA) via (ii) relative recovery correction at midpoint of the collection interval (midpoint-NCA, midpoint-CA) and (ii) dialysate-based integrals of time (integral-CA). Exposure and adequacy of community-acquired pneumonia (CAP) therapy via pharmacokinetic/pharmacodynamic target-attainment (PTA) analysis were compared between approaches. RESULTS: Individual AUCISF estimates strongly varied for midpoint-NCA and midpoint-CA (≥52.3%CV) versus integral-CA (≤32.9%CV) owing to separation of variability in PK parameters (midpoint-CA = 46.5%-143%CVPK, integral-CA = 26.4%-72.6%CVPK) from recovery-related variability only in integral-CA (41.0%-50.3%CVrecovery). This also led to increased variability of AUCplasma for midpoint-CA (56.0%CV) versus midpoint-NCA and integral-CA (≤33.0%CV), and inaccuracy of predictive model performance of midpoint-CA in plasma (visual predictive check). PTA analysis translated into 33% of evaluated patient cases being at risk of incorrectly rejecting recommended dosing regimens at CAP-related epidemiological cut-off values. CONCLUSIONS: Integral-CA proved most appropriate to characterise clinical pharmacokinetics- and microdialysis-related variability. Employing this knowledge will improve the understanding of drug target-site PK for therapeutic decision-making.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Microdiálisis / Levofloxacino / Antibacterianos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Pharm Res Año: 2021 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Microdiálisis / Levofloxacino / Antibacterianos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Pharm Res Año: 2021 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos